Skip to content
Ataraxis AI, a laboratory pioneering AI-powered oncology tools, has announced a strategic collaboration with Medica Scientia Innovation Research (MEDSIR) to bring artificial intelligence into international breast cancer trials.
The collaboration spans data from over 1,000 patients across randomised clinical trials. Its aim: identify biomarkers to optimise treatment strategies, including therapies with CDK4/6 inhibitors and antibody-drug conjugates (ADCs).
Ataraxis Breast, the company’s AI-native platform, integrates insights from digital pathology slides and clinical data to predict patient outcomes and treatment responses. This helps clinicians choose the right drug for the right patient — a growing challenge as new therapies proliferate.
MEDSIR, a long-time leader in oncology trials, views the partnership as a milestone in precision oncology. Alicia García, MEDSIR’s Scientific Director, said:
“Partnering with Ataraxis AI allows us to integrate cutting-edge artificial intelligence into clinical trials, generating evidence that can transform treatment decision-making in breast cancer.”
The collaboration builds on Ataraxis’ earlier validations across breast cancer subtypes and moves the platform from retrospective studies into prospective clinical trials. By doing so, it aims to embed AI-driven decision-making into standard oncology practice worldwide.
With MEDSIR’s global network of 600 researchers and Ataraxis’ partnerships with more than 40 institutions, the partnership has the potential to reshape breast cancer research and accelerate access to life-saving treatments.
Read the full story here.
